DIAGENS-B (02526) surged more than 9% in late trading. As of the latest update, the stock rose 9.01% to HK$326.8, with a turnover of HK$40,489,400.

The company recently disclosed its 2025 performance. Annual total revenue reached RMB 164 million, a sharp increase of 133.7% year-on-year. Gross profit was RMB 118 million, surging 157% compared to the previous year.

Financial reports indicate that revenue from the company's technology licensing business skyrocketed to RMB 84.34 million from RMB 19.54 million in the same period last year, a massive increase of 331.7%. This segment accounted for half of the total revenue for the first time, becoming the largest income source. The gross profit margin for the technology licensing business is close to 87.3%, nearly reaching the theoretical ceiling for the model service industry.

The 2025 annual report serves as the most powerful demonstration of the company's capabilities to date. The 332% surge in technology licensing revenue validates the feasibility of the commercial closed-loop for its large model. A market share of 30.6% maintains its absolute leading position in a policy-driven, essential sector. Furthermore, the endorsement of its iMedImage® foundational model by leading institutions such as Tencent profoundly confirms its strategic value as a global AI medical infrastructure service provider.